| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA448: Etelcalcetide for treating secondary hyperparathyroidism |
|
Medicine details |
|
| Medicine name | etelcalcetide (Parsabiv®) |
| Formulation | 2.5 mg, 5 mg and 10 mg solution for injection |
| Reference number | 3312 |
| Indication | Treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on haemodialysis therapy |
| Company | Amgen Ltd |
| BNF chapter | Nutrition & blood |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 22/11/2016 |
| NICE guidance | TA448: Etelcalcetide for treating secondary hyperparathyroidism |